Chronic cough

Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders

Retrieved on:

Wednesday, April 3, 2024

With initial funding of $63 million from Perceptive Xontogeny Venture Fund II, with participation from Perceptive Life Sciences Fund and Acorn Bioventures, Neurosterix will acquire a portfolio of preclinical assets and the allosteric modulator drug discovery technology platform from Addex and accelerate their development.

Key Points:

With initial funding of $63 million from Perceptive Xontogeny Venture Fund II, with participation from Perceptive Life Sciences Fund and Acorn Bioventures, Neurosterix will acquire a portfolio of preclinical assets and the allosteric modulator drug discovery technology platform from Addex and accelerate their development.
In return, Addex will receive CHF5 million and a 20% equity interest in Neurosterix.
“The launch of Neurosterix in partnership with Perceptive is an important validation of the Addex allosteric modulator drug discovery technology platform and provides the resources to accelerate development of important preclinical assets, including the M4 PAM and mGlu7 negative allosteric modulator (NAM) programs, into the clinic,” said Tim Dyer, CEO of Addex.
To guide the launch of Neurosterix, Tim Dyer, in addition to his role at Addex, will assume the role of CEO of Neurosterix.

Algernon Pharmaceuticals Announces Closing of the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position

Retrieved on:

Wednesday, March 27, 2024

Algernon, Brain, Drug discovery, Letter, NMDA, Acquisition, Patient, AGN, Ifenprodil, IPF, Idiopathic pulmonary fibrosis, USD, Chronic cough, Food, Pharmaceutical industry

The Company previously announced on November 22, 2003 that it had signed a Letter of Intent with Seyltx, to acquire Algernon’s Ifenprodil research program.

Key Points:

The Company previously announced on November 22, 2003 that it had signed a Letter of Intent with Seyltx, to acquire Algernon’s Ifenprodil research program.
Ifenprodil is an N-methyl-D-aspartate (“NMDA”) receptor antagonist specifically targeting the NMDA type subunit 2B (GluN2B), which prevents glutamate signaling.
Ifenprodil is one of Algernon’s lead research programs and represents a novel first-in-class potential treatment for chronic cough.
It is thought to interfere with central signalling in the brain, suppressing the urge to cough.

Trevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conference

Retrieved on:

Tuesday, April 9, 2024

MB, NHS foundation trust, Conference, ATS, NIHR, University of Manchester, University, Doctor of Philosophy, Respiratory Medicine, American Thoracic Society, Chronic cough, FRCP, IPF, Idiopathic pulmonary fibrosis, RCC, Therapy

NEW HAVEN, Conn., April 9, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that data from the Phase 2 CANAL trial will be presented at the American Thoracic Society (ATS) 2024 International Conference being held in San Diego, CA, from May 17-22. The presentation will take place on May 19th.

Key Points:

NEW HAVEN, Conn., April 9, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that data from the Phase 2 CANAL trial will be presented at the American Thoracic Society (ATS) 2024 International Conference being held in San Diego, CA, from May 17-22.
The presentation will take place on May 19th.
Presenter: Jacky Smith, MB, ChB, FRCP, PhD, Professor of Respiratory Medicine at the University of Manchester, and an Honorary Consultant at Manchester University NHS Foundation Trust.
Director of the NIHR Manchester Clinical Research Facility, Respiratory Theme Lead in the NIHR Manchester Biomedical Research Centre and an NIHR Senior Investigator.

Trevi Therapeutics to Participate in Upcoming April Events

Retrieved on:

Thursday, April 4, 2024

Chronic cough, Webcast, News, Conference, IPF, Idiopathic pulmonary fibrosis, RCC, Therapy

NEW HAVEN, Conn., April 4, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will attend and participate in the following events in April.

Key Points:

NEW HAVEN, Conn., April 4, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will attend and participate in the following events in April.
A live webcast of the 23rd Annual Needham Virtual Healthcare Conference fireside chat will be accessible from the 'Investors & News' section on the Company's website at www.TreviTherapeutics.com .
An archived replay of the webcast will also be available for 30 days on the Company's website following the event.

Trevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership Team

Retrieved on:

Tuesday, April 2, 2024

Science, Teva Pharmaceuticals, GSK, Executive, Inflammation, Patient, Knowledge, MD, Cough, Drug, Trevi, IPF, Idiopathic pulmonary fibrosis, Medical school, RCC, Therapy, Chronic cough, Pharmaceutical industry

NEW HAVEN, Conn., April 2, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced the appointment of Margaret Garin, MD, MSCR, as Vice President of Clinical Development. Dr. Garin will be responsible for progressing the clinical development of Haduvio in chronic cough and brings unique and relevant experience from her previous lead role in clinical development at Bellus Health.

Key Points:

Dr. Garin will be responsible for progressing the clinical development of Haduvio in chronic cough and brings unique and relevant experience from her previous lead role in clinical development at Bellus Health.
Her background spans various stages of the clinical development process including both strategic and executional roles, as well as the science of cough.
"I am happy to welcome Meg to our team," said David Clark, Chief Medical Officer of Trevi Therapeutics.
I am thrilled to have the ability to continue my work in chronic cough by joining the Trevi team to further the development of Haduvio for these patients."

Trevi Therapeutics to Report Q4 and Year End 2023 Financial Results and Provide a Corporate Update on March 20, 2024

Retrieved on:

Wednesday, March 13, 2024

Chronic cough, Webcast, Patient, News, Conference call, IPF, Idiopathic pulmonary fibrosis, RCC, Therapy

NEW HAVEN, Conn., March 13, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for patients with chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio webcast on Wednesday, March 20, 2024, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the quarter and year ended December 31, 2023.

Key Points:

ET, to provide a corporate update and review the Company's financial results for the quarter and year ended December 31, 2023.
To participate in the live conference call by phone, please dial (888) 317 6003 (domestic) or (412) 317 6061 (international) and provide access code 4401006.
A live audio webcast will be accessible from the 'Investors & News' section on the Company's website at www.TreviTherapeutics.com .
An archived replay of the webcast will also be available for 30 days on the Company's website following the event.

Nocion Therapeutics Announces $62 Million Series B Financing to Advance Lead Program in Cough into Later Stage Development

Retrieved on:

Monday, March 4, 2024

Nocion Therapeutics, a clinical-stage biopharmaceutical company, today announced that it has raised $62 million in Series B funding.

Key Points:

Nocion Therapeutics, a clinical-stage biopharmaceutical company, today announced that it has raised $62 million in Series B funding.
Proceeds from the financing will be used to evaluate the lead program, Taplucanium Dry Powder for Inhalation, in a Phase 2b study in Chronic Cough patients.
With this financing, Nocion has raised $122 million since the company was founded in 2018.
“We are grateful to our new and existing investors for their commitment to our lead program in this challenging disease,” said Dr. Richard Batycky, Chief Executive Officer of Nocion.

Trevi Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Retrieved on:

Tuesday, February 6, 2024

RCC, Idiopathic pulmonary fibrosis, Therapy, Patient, Chronic cough, Webcast, IPF, Conference, News

NEW HAVEN, Conn., Feb. 6, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for patients with chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that Jennifer Good, President and Chief Executive Officer, will be presenting at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Wednesday, February 14, at 10:00 a.m. ET. During this virtual event, Ms. Good along with Lisa Delfini, Chief Financial Officer, will also participate in investor meetings with attendees.

Key Points:

ET
NEW HAVEN, Conn., Feb. 6, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for patients with chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that Jennifer Good, President and Chief Executive Officer, will be presenting at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Wednesday, February 14, at 10:00 a.m.
During this virtual event, Ms. Good along with Lisa Delfini, Chief Financial Officer, will also participate in investor meetings with attendees.
A live webcast will be accessible from the 'Investors & News' section on the Company's website at www.TreviTherapeutics.com .
An archived replay of the webcast will also be available for 30 days on the Company's website following the event.

Addex to Present at Biotech Showcase™ 2024

Retrieved on:

Friday, January 5, 2024

For more information or to schedule a one-on-one meeting, please submit a request via the Biotech Showcase partnering platform or by sending an email to [email protected] .

Key Points:

For more information or to schedule a one-on-one meeting, please submit a request via the Biotech Showcase partnering platform or by sending an email to [email protected] .
Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available, small molecule drugs known as allosteric modulators for neurological disorders.
Addex’s allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention.
Indivior PLC has licensed Addex’s GABAB PAM program for the development of drug candidates, with a focus on substance use disorder.

Trevi Therapeutics Provides Business Updates

Retrieved on:

Thursday, January 4, 2024

Conference, Clutch (eggs), Idiopathic pulmonary fibrosis, IPF, Brain, Therapy, RCC, Trevi, Patient, Chronic cough, Pharmaceutical industry

NEW HAVEN, Conn., Jan. 4, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for patients with chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced a preview of business updates.

Key Points:

NEW HAVEN, Conn., Jan. 4, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for patients with chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced a preview of business updates.
Management will be attending the 13th Annual LifeSci Partners Corporate Access Event in San Francisco from January 8-10 and will be available to discuss updates.
This event takes place during the week of the annual J.P. Morgan Health Care Conference.
"Our team is very excited about Trevi's outlook for 2024 having initiated two clinical trials in chronic cough and the Human Abuse Potential study late in 2023," said Jennifer Good, President and CEO of Trevi Therapeutics.